Biopharmaceutical company Alnylam Pharmaceuticals has received orphan drug designations for ALN-AT3 from the European Medicines Agency (EMA) Committee to treat haemophilia A and B.
ALN-AT3 is a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for treating haemophilia and other rare bleeding disorders (RBD).
Go deeper with GlobalData
Alnylam Pharmaceuticals regulatory affairs and quality assurance senior vice-president Saraswathy Nochur said: "We are very pleased to have received orphan drug designations from the EMA COMP for ALN-AT3, a key programme in our Alnylam 5×15 product development and commercialisation strategy.
"We believe that our subcutaneously delivered RNAi therapeutic represents an innovative approach for the management of haemophilia and has great potential to make a meaningful impact in the treatment of this often debilitating bleeding disorder."
Alnylam noted that ALN-AT3 is currently being investigated in a multinational Phase I trial.
The company presented positive top-line data from part A of the study performed in healthy adult volunteers at the World Federation of Haemophilia 2014 World Congress held in May.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataA total of 18 people with moderate to severe haemophilia A or B have been enrolled in part B open-label, multi-dose, dose-escalation study.
This study’s primary objective is to evaluate the safety and tolerability of three weekly doses of subcutaneously administered ALN-AT3 in haemophilia subjects.
The clinical activity assessment, determined by the knockdown of circulating AT levels and increase in thrombin generation at pharmacologic doses of ALN-AT3, makes up the secondary objective.
Results from part B of the study are expected to be presented by the end of the year.
